GEMP taking another huge hit - down 64% - said a phase 2a trial of its treatment for non-alcoholic fatty liver disease in pediatric patients will be terminated, citing "unanticipated problems."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.